These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6876571)

  • 1. Separation of one uremic middle molecules fraction by high performance liquid chromatography.
    Gallice P; Fournier N; Crevat A; Briot M; Frayssinet R; Murisasco A
    Kidney Int; 1983 May; 23(5):764-6. PubMed ID: 6876571
    [No Abstract]   [Full Text] [Related]  

  • 2. Separation of six uremic middle molecular compounds by high performance liquid chromatography and analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    Chu J; Yuan Z; Liu X; Wu Q; Mi H; He B
    Clin Chim Acta; 2001 Sep; 311(2):95-107. PubMed ID: 11566169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Separation, identification of uremic middle molecules, and preliminary study on their toxicity.
    Li G; Chu J; Liu X; Yuan Z
    Clin Chim Acta; 2004 Dec; 350(1-2):89-98. PubMed ID: 15530464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Middle molecules and the 7 C factor.
    Bergström J; Jörnvall H; Zimmerman L
    Adv Exp Med Biol; 1987; 223():27-32. PubMed ID: 3447445
    [No Abstract]   [Full Text] [Related]  

  • 5. A compound from uremic plasma and from normal urine isolated by liquid chromatography and identified by nuclear magnetic resonance.
    Gallice P; Monti JP; Crevat A; Durand C; Murisasco A
    Clin Chem; 1985 Jan; 31(1):30-4. PubMed ID: 3965216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retention patterns.
    Schoots A; Vanholder R; Ringoir S; Cramers C
    Adv Exp Med Biol; 1987; 223():19-26. PubMed ID: 3447434
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibition of microtubule formation by uremic toxins: action mechanism and hypothesis about the active component.
    Braguer D; Gallice P; Monti JP; Murisasco A; Crevat A
    Clin Nephrol; 1986 Apr; 25(4):212-8. PubMed ID: 3698354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Separation, isolation, and identification of middle molecules.
    Bergström J; Fürst P; Zimmerman L
    Artif Organs; 1981; 4 Suppl():5-7. PubMed ID: 7295096
    [No Abstract]   [Full Text] [Related]  

  • 9. Improved separation and quantification of the "middle molecule" b4-2 in uremia.
    Faguer P; Man NK; Cueille G; Di Giulio S; Funck-Brentano JL
    Clin Chem; 1983 Apr; 29(4):703-7. PubMed ID: 6831703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical study for separation of middle molecules.
    Saito A; Kanazawa I; Chung TG; Maeda K
    Artif Organs; 1981; 4 Suppl():13-6. PubMed ID: 6975092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The fraction b 4-2: isolation, characterization and biological activities with reference to uremic polyneuropathy.
    Man NK; Cueille G; Faguer P; Boudet J; Pierrat D; Zingraff J; Sausse A; Funck-Brentano JL
    Adv Exp Med Biol; 1987; 223():135-40. PubMed ID: 3447428
    [No Abstract]   [Full Text] [Related]  

  • 12. A method for separation of middle molecules by high performance liquid chromatography: application in studies of glucuronyl-o-hydroxyhippurate in normal and uremic subjects.
    Zimmerman L; Bergström J; Jörnvall H
    Clin Nephrol; 1986 Feb; 25(2):94-100. PubMed ID: 3698350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of plasma middle molecular fraction in uremic patients.
    Kovalishin YaF
    Biomater Artif Cells Artif Organs; 1987; 15(3):605-10. PubMed ID: 3440134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Methodology of uremic toxin analysis].
    Tamura Z
    Nihon Jinzo Gakkai Shi; 1976 Jun; 18(6):423-4. PubMed ID: 988346
    [No Abstract]   [Full Text] [Related]  

  • 15. Analysis of small peptide in uremic serum by high-performance liquid chromatography.
    Mabuchi H; Nakahashi H
    J Chromatogr; 1982 Mar; 228():292-7. PubMed ID: 7076752
    [No Abstract]   [Full Text] [Related]  

  • 16. Search for peptidic "middle molecules" in uremic sera: isolation and chemical identification of fibrinogen fragments.
    Kaplan B; Cojocaru M; Unsworth E; Knecht A; Martin BM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Oct; 796(1):141-53. PubMed ID: 14552825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation and identification of canine plasma components suspected as uremic toxins.
    Kawamura M; Ohashi F; Nagata Y; Takai N; Motoie H; Nishimura R; Sasaki N; Takeuchi A
    J Vet Med Sci; 1993 Apr; 55(2):265-70. PubMed ID: 8513007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Membrane and chromatography separation techniques for the preparative isolation of uremic toxins.
    Brunner H; Mann H
    Life Support Syst; 1983; 1 Suppl 1():199-206. PubMed ID: 6336410
    [No Abstract]   [Full Text] [Related]  

  • 19. [Uremic middle-molecule toxins and their removal in hemofiltration].
    Kazakov IV; Timokhov VS
    Urol Nefrol (Mosk); 1991; (1):67-73. PubMed ID: 1858215
    [No Abstract]   [Full Text] [Related]  

  • 20. Isotachophoretic separation of middle molecule peptides in uremic body fluids.
    Zimmerman L; Baldesten A; Bergström J; Fürst P
    Clin Nephrol; 1980 Apr; 13(4):183-8. PubMed ID: 7379369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.